The number of breathing pauses and shallow breaths an hour fell by 25.3 and 29.3 on tirzepatide, against about 5 on placebo. The results led to Zepbound's approval for sleep apnea and were published in the New England Journal of Medicine in 2024.1,2
The measure: the apnea-hypopnea index
Sleep apnea is graded by the apnea-hypopnea index, or AHI: the number of apneas, pauses in breathing, and hypopneas, shallow breaths, during an hour of sleep.1 The trials enrolled people with an AHI of 15 or more, moderate to severe apnea, and a body mass index of 30 or more.2 At the start, the average AHI was 51.5 in the first trial and 49.5 in the second, with average body mass indexes of 39.1 and 38.7.1
How the trials were run
Trial 1 enrolled people who were not using positive airway pressure, the breathing machine often prescribed for sleep apnea; trial 2 enrolled people who were using it. The label gives their sizes as 234 and 235 people. In both, participants were assigned in equal numbers to the highest dose of tirzepatide they tolerated, 10 mg or 15 mg, or placebo, for 52 weeks.1
What they found
- Without the machine: AHI fell by 25.3 events an hour on tirzepatide and 5.3 on placebo, a difference of 20.0.
- With the machine: AHI fell by 29.3 on tirzepatide and 5.5 on placebo, a difference of 23.8.
- All the main secondary measures set in advance improved on tirzepatide.
Malhotra et al., 2024.1
The Zepbound label adds detail from the same trials. Remission or mild apnea without symptoms was reached by 42.2% on tirzepatide against 15.9% on placebo in the first trial, and 50.2% against 14.3% in the second. The label defines that as an AHI under 5, or an AHI of 5 to 14 with a score of 10 or less on the Epworth Sleepiness Scale, a questionnaire about how easily a person dozes off in daily situations. Weight fell by 17.7% and 19.6% on tirzepatide, against 1.6% and 2.3% on placebo.2
What it changed
On the basis of these trials, Zepbound is approved to treat moderate to severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and more physical activity. For sleep apnea the maintenance dose is 10 mg or 15 mg a week.2 Mounjaro, the same molecule for type 2 diabetes, does not carry this use.3
How to read the result
A fall from about 50 to about 22 or 25 events an hour is large, but for many people it still leaves an AHI above 15, the threshold for moderate apnea. That is why the second trial matters: people who kept using their machine still gained from tirzepatide. Whether someone can stop using their machine is a question for their sleep doctor and a repeat sleep study, not something the trial result decides.
Side effects
The most frequent adverse events with tirzepatide were in the stomach and gut.1 Our Zepbound side effects timeline shows when they tend to start and fade.
Limits
The trials lasted one year and enrolled people with obesity only, so they do not show whether tirzepatide helps sleep apnea in people of lower weight. They were funded by Eli Lilly, the maker of tirzepatide.1
Sources
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med 2024;391:1193-1205. Funded by Eli Lilly; NCT05412004. doi:10.1056/NEJMoa2404881
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2, 6.1 and 14.2. accessdata.fda.gov
- MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; section 1. accessdata.fda.gov
Related analyses
Zepbound dosing schedule: every step from 2.5 to 15 mg, with your dates
Mounjaro vs Zepbound: the same drug under two labels, compared by use, results and price
Zepbound cost: what you pay with insurance, without it, and over a year
Zepbound side effects timeline: when they start, how long they last, when they ease
Log your weight and how you sleep, and see whether they move together.
Open Dose Insider